FitLife Brands stays profitable, buys Irwin amid revenue slide and rising M&A costs

FitLife Brands, Inc. (OTCMKTS: FTLF) - Quick internal and income-statement snapshot

* What's happening now: management is executing M&A (deposit of $5,000 on Irwin acquisition recorded at June 30, 2025; acquisition closed Aug 8, 2025 for ~ $42,500). The company refinanced and upsized credit facilities post‑quarter (new Term Loan $40,625 and new $10,000 revolver) and used proceeds to buy Irwin and retire prior debt.

* Key balance-sheet facts (June 30, 2025): Total assets $62,847; Total liabilities $21,928; Total stockholders' equity $40,919. Cash & cash equivalents $1,530 (restricted cash $55). Working capital $9,209. Term loans outstanding (per note) ~$10,875; notes payable on books $10,821 (current $4,500 / long‑term $6,321).

* Cash flow / liquidity: Net cash provided by operations (six months) $3,523. Cash and restricted cash ended at $1,585 (down from $4,520 start), largely impacted by a $5,000 deposit for Irwin and term‑loan activity.

Income-statement positives
* The company remains profitable: Q2 2025 net income $1,747 (six months $3,765). Basic EPS Q2 $0.19; six months basic EPS $0.40.
* Positive operating income: Q2 operating income $2,518 and consolidated EBITDA (Q2) $2,532; adjusted EBITDA (Q2) $3,327 - shows underlying cash‑earnings support.
* Gross margins remain healthy despite pressure: Q2 gross margin 42.8% (six months 43.0%) - still respectable for consumer supplements and DTC/wholesale mix.

Income-statement negatives / red flags
* Revenue contraction: Q2 revenue $16,127, down 5% vs Q2 2024 ($16,930). Six months revenue $32,063, down 4% vs prior year ($33,479). Declines driven mainly by MRC (Q2 MRC revenue $6,269, down 16% YoY) and weaker MusclePharm wholesale.
* Margin pressure from product mix, tariffs and promotions: Q2 gross margin fell from 44.8% to 42.8% (mix shift, tariffs on skin-care products, and MusclePharm promotional spend).
* Rising M&A costs: merger & acquisition related expense jumped to $696 in Q2 (six months $1,028) - directly hit operating income and adjusted EBITDA trends.
* Declining net income and operating income: Q2 net income fell 34% YoY and operating income dropped 31% YoY - primarily due to lower revenue/gross profit and higher transaction costs.

Operational / concentration risks worth noting
* Customer concentration: GNC accounted for ~22% of Q2 sales and ~28% of gross AR at June 30, 2025 - still a meaningful concentration risk.
* Channel concentration: Online sales ~65% of Q2 revenue (wholesale ~35%) - digital performance (Amazon traffic) materially affects results (MRC declines tied to Amazon traffic drop).
* Leverage & covenants: company has sizable term debt; new Credit Agreement imposes senior funded‑debt/EBITDA and fixed charge coverage covenants (management reported covenant compliance at June 30, 2025).

* Management actions: reduced ad spend on low‑return campaigns (advertising down 10% Q2 YoY), continuing targeted promotional investments for MusclePharm, and pursuing roll‑up growth (Irwin acquisition) to diversify brands and scale.

One‑line takeaways
* For shareholders: profitable and cash‑generating, but near‑term earnings are being pressured by lower revenue at acquired brands, tariffs, promotional investments, and rising M&A costs. The Irwin deal expands the brand set but increases leverage and integration risk.
* Watch next moves on: post‑acquisition integration of Irwin, the company's ability to restore MRC growth (Amazon traffic), free‑cash‑flow after the $42.5M purchase, and covenant metrics on the new credit facility.

Source: FitLife Brands, Inc. - Form 10‑Q for quarter ended June 30, 2025 (figures and notes quoted directly).